TransMedics Faces 2nd Panel Date Postponement
Will the third time be the charm?
The company said the postponement will give the US FDA additional time to review trial data.
You may also be interested in...
The US FDA will host an advisory committee webcast to discuss approval of the company’s new heart transplant device a year after it was originally planned.
The US agency’s circulatory system devices panel will take up the company’s heart transplant tool in an October virtual session.
The government collected $2.68bn from settled False Claims Act cases last year, the US Department of Justice said. Another 12 device-related cases were announced in February alone.